TRAV1-2

Across TCGA pan-cancer cohorts, TRAV1-2 Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated TRAV1-2 data layer compared with 26 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher TRAV1-2 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated TRAV1-2 expression acts as an unfavorable survival marker.

ESCA and LUAD are the cancer types where TRAV1-2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	DFS	Median	II,III,IV	0.082	0.523	<.001	12	view →
LUAD	DFS	Median	All	0.244	0.791	.007	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

TRAV1-2–ESCA (DFS)

Open the ESCA breakdown →